Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
You may also be interested in...
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
Japanese firm's goal is to consolidate resources to enhance it's prescription drug pipeline, maximize Crestor (rosuvastatin) product value, and strengthen domestic marketing and overseas expansion.
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
Japanese firm's goal is to consolidate resources to enhance it's prescription drug pipeline, maximize Crestor (rosuvastatin) product value, and strengthen domestic marketing and overseas expansion.
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
Osaka-based Shionogi's board of directors agreed to transfer wholly owned Bushu Pharmaceuticals to private investment fund TMC BUYOUT1, a subsidiary of Tokio Marine Capital beginning March 31. Bushu is the second-largest pharmaceutical contract manufacturer in Japan